Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment

PLoS Neglected Tropical Diseases

Volumn 10, Issue 5, 2016, Pages

  Tientcheu, Leopold D ^a,b,c   Haks, Mariëlle C ^d   Agbla, Schadrac C ^a,b   Sutherland, Jayne S ^a   Adetifa, Ifedayo M ^b,e   Donkor, Simon ^a   Quinten, Edwin ^d   Daramy, Mohammed ^a   Antonio, Martin ^a,b,f   Kampmann, Beate ^a   Ottenhoff, Tom H M ^d   Dockrell, Hazel M ^b   Ota, Martin O ^a,g  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Medical Research Council Unit   (Gambia)

^f UNIVERSITY OF WARWICK   (United Kingdom)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 8; ISONIAZID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PYRAZINAMIDE; RIFAMPICIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; CYTOKINE; ESAT-6 ANTIGEN, MYCOBACTERIUM LEPRAE; IL5 PROTEIN, HUMAN; INTERLEUKIN 5; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MYCOBACTERIUM AFRICANUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUESTIONNAIRE; RNA EXTRACTION; SKINFOLD THICKNESS; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TUBERCULOSIS; ADOLESCENT; AGED; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; ETHNOLOGY; GAMBIA; HOST PATHOGEN INTERACTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BIOMARKERS; CYTOKINES; FEMALE; GAMBIA; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-5; INTERLEUKIN-8; MALE; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84971595047     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004701     Document Type: Article

References (60)

1. de Jong BC, Antonio M, Gagneux S, Mycobacterium africanum-review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis. 2010; 4(9):e744. doi: 10.1371/journal.pntd.000074420927191
2. Gagneux S, Host-pathogen coevolution in human tuberculosis. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2012; 367(1590):850–9. doi: 10.1098/rstb.2011.031622312052
3. Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, Rozakeas F, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One. 2012; 7(10):e46191. doi: 10.1371/journal.pone.004619123056259
4. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis. 2013; 207(1):18–29. doi: 10.1093/infdis/jis49922872737
5. Cliff JM, Kaufmann SH, McShane H, van Helden P, O'Garra A, The human immune response to tuberculosis and its treatment: a view from the blood. Immunol Rev. 2015; 264(1):88–102. doi: 10.1111/imr.1226925703554
6. Click ES, Winston CA, Oeltmann JE, Moonan PK, Mac Kenzie WR, Association between Mycobacterium tuberculosis lineage and time to sputum culture conversion. Int J Tuberc Lung Dis. 2013; 17(7):878–84. doi: 10.5588/ijtld.12.073223743308.
7. Coscolla M, Gagneux S, Consequences of genomic diversity in Mycobacterium tuberculosis. Seminars in immunology. 2014; 26(6):431–44. doi: 10.1016/j.smim.2014.09.01225453224
8. Gumbo T, Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet. 2013; 45(7):720–1. doi: 10.1038/ng.267523800865
9. Coussens AK, Wilkinson RJ, Nikolayevskyy V, Elkington PT, Hanifa Y, Islam K, et al. Ethnic variation in inflammatory profile in tuberculosis. PLoS Pathog. 2013; 9(7):e1003468. doi: 10.1371/journal.ppat.100346823853590
10. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013; 45(7):784–90. doi: 10.1038/ng.265623749189
11. Pareek M, Evans J, Innes J, Smith G, Hingley-Wilson S, Lougheed KE, et al. Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. Thorax. 2013; 68(3):221–9. doi: 10.1136/thoraxjnl-2012-20182423019255.
12. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, et al. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010; 5(5):e10753. doi: 10.1371/journal.pone.001075320505778
13. Tientcheu LD, Maertzdorf J, Weiner J, Adetifa IM, Mollenkopf HJ, Sutherland JS, et al. Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment. Genes Immun. 2015; 16(5):347–55. doi: 10.1038/gene.2015.2126043170;
14. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014; 371(17):1588–98. doi: 10.1056/NEJMoa131581725337748.
15. Tientcheu LD, Sutherland JS, de Jong BC, Kampmann B, Jafali J, Adetifa IM, et al. Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients. Eur J Immunol. 2014; 44(5):1387–98. doi: 10.1002/eji.20134395624481948.
16. de Jong BC, Hill PC, Aiken A, Jeffries DJ, Onipede A, Small PM, et al. Clinical presentation and outcome of tuberculosis patients infected by M. africanum versus M. tuberculosis. Int J Tuberc Lung Dis. 2007; 11(4):450–6. 17394693.
17. de Jong BC, Antonio M, Awine T, Ogungbemi K, de Jong YP, Gagneux S, et al. Use of spoligotyping and large sequence polymorphisms to study the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear-positive tuberculosis cases in The Gambia. J Clin Microbiol. 2009; 47(4):994–1001. doi: 10.1128/JCM.01216-0819193842
18. WHO. Treatment of tuberculosis GUIDELINES Fourth edition World Health Organisation. 2010. http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf
19. Galagan JE, Sisk P, Stolte C, Weiner B, Koehrsen M, Wymore F, et al. TB database 2010: overview and update. Tuberculosis (Edinb). 2010; 90(4):225–35. 20488753.
20. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun. 2012; 13(1):71–82. doi: 10.1038/gene.2011.6421956656.
21. Satti L, Ikram A, Abbasi S, Malik N, Mirza IA, Martin A, Evaluation of thin-layer agar 7H11 for the isolation of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis. 2010; 14(10):1354–6. 20843431.
22. Reuter MA, Pecora ND, Harding CV, Canaday DH, McDonald D, Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells. J Virol. 2010; 84(17):8549–60. doi: 10.1128/JVI.02303-0920592078
23. Sidak Z, Rectangular confidence regions for the means of multivariate normal distributions. J Amer Stat Assoc1967; 62:626–33.
24. Wang J, Yin Y, Wang X, Pei H, Kuai S, Gu L, et al. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis. 2015; 19(2):125–31. doi: 10.1016/j.bjid.2014.10.00825529365.
25. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005; 175(2):788–95. 175/2/788 [pii]. 16002675.
26. Kay MK, Linke L, Triantis J, Salman MD, Larsen RS, Evaluation of DNA extraction techniques for detecting Mycobacterium tuberculosis complex organisms in Asian elephant trunk wash samples. J Clin Microbiol. 2011; 49(2):618–23. doi: 10.1128/JCM.00807-1021159933
27. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A, TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med. 2005; 202(12):1715–24. doi: 10.1084/jem.2005178216365150
28. O'Sullivan DM, McHugh TD, Gillespie SH, Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol. 2010; 59(12):1533–5. doi: 10.1099/jmm.0.019091–020724506
29. Yu CC, Chang CY, Liu CE, Shih LF, Hsiao JH, Chen CH, Drug resistance pattern of Mycobacterium tuberculosis complex at a medical center in central Taiwan, 2003–2007. J Microbiol Immunol Infect. 2010; 43(4):285–90. doi: 10.1016/S1684-1182(10)60045-X20688288.
30. Umemura M, Nishimura H, Hirose K, Matsuguchi T, Yoshikai Y, Overexpression of IL-15 in vivo enhances protection against Mycobacterium bovis bacillus Calmette-Guerin infection via augmentation of NK and T cytotoxic 1 responses. J Immunol. 2001; 167(2):946–56. 11441103.
31. Maeurer MJ, Trinder P, Hommel G, Walter W, Freitag K, Atkins D, et al. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect Immun. 2000; 68(5):2962–70. 10768995
32. Mihret A, Abebe M, Bekele Y, Aseffa A, Walzl G, Howe R, Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis. 2014; 14:125. doi: 10.1186/1471-2334-14-12524592945
33. Shakoor S, Ahsan T, Jabeen K, Raza M, Hasan R, Use of p-nitrobenzoic acid in 7H10 agar for identification of Mycobacterium tuberculosis complex: a field study. Int J Tuberc Lung Dis. 2010; 14(12):1644–6. 21144253.
34. de Jong BC, Hill PC, Brookes RH, Otu JK, Peterson KL, Small PM, et al. Mycobacterium africanum: a new opportunistic pathogen in HIV infection?AIDS. 2005;19(15):1714–5. 00002030-200510140-00030. 16184053.
35. de Jong BC, Adetifa I, Walther B, Hill PC, Antonio M, Ota M, et al. Differences between tuberculosis cases infected with Mycobacterium africanum, West African type 2, relative to Euro-American Mycobacterium tuberculosis: an update. FEMS Immunol Med Microbiol. 2010; 58(1):102–5. doi: 10.1111/j.1574-695X.2009.00628.x20002176
36. Jackson-Sillah D, Cliff JM, Mensah GI, Dickson E, Sowah S, Tetteh JK, et al. Recombinant ESAT-6-CFP10 Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. PLoS One. 2013; 8(6):e68121. doi: 10.1371/journal.pone.006812123826366
37. Mensah GI, Addo KK, Tetteh JA, Sowah S, Loescher T, Geldmacher C, et al. Cytokine response to selected MTB antigens in Ghanaian TB patients, before and at 2 weeks of anti-TB therapy is characterized by high expression of IFN-gamma and Granzyme B and inter- individual variation. BMC Infect Dis. 2014; 14:495. doi: 10.1186/1471-2334-14-49525209422
38. Mattos AM, Almeida Cde S, Franken KL, Alves CC, Abramo C, de Souza MA, et al. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol. 2010;22(9):775–82. doi: 10.1093/intimm/dxq42920624776
39. Kaneko Y, Nakayama K, Kinoshita A, Kurita Y, Odashima K, Saito Z, et al. Relation between recurrence of tuberculosis and transitional changes in IFN-gamma release assays. Am J Respir Crit Care Med. 2015; 191(4):480–3. doi: 10.1164/rccm.201409-1590LE25679108.
40. Kaewseekhao B, Naranbhai V, Roytrakul S, Namwat W, Paemanee A, Lulitanond V, et al. Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment. PLoS One. 2015; 10(7):e0134168. doi: 10.1371/journal.pone.013416826214306
41. Huang KH, Wang CH, Lin CH, Kuo HP, NF-kappaB repressing factor downregulates basal expression and Mycobacterium tuberculosis induced IP-10 and IL-8 synthesis via interference with NF-kappaB in monocytes. Journal of biomedical science. 2014; 21:71. doi: 10.1186/s12929-014-0071-525135111
42. Ning BF, Ding J, Liu J, Yin C, Xu WP, Cong WM, et al. Hepatocyte nuclear factor 4alpha-nuclear factor-kappaB feedback circuit modulates liver cancer progression. Hepatology. 2014. doi: 10.1002/hep.2717724752868.
43. WHOGlobal Tuberculosis Report 2015. World Health Organization2015;20th Edition. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
44. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(6):387–94. doi: 10.1016/S1473-3099(10)70071-220510279
45. Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, Sillah J, et al. Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis. 2003; 7(4):390–3. 12729346
46. Yeboah-Manu D, Asante-Poku A, Bodmer T, Stucki D, Koram K, Bonsu F, et al. Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One. 2011; 6(7):e21906. doi: 10.1371/journal.pone.002190621779354
47. Traore B, Diarra B, Dembele BP, Somboro AM, Hammond AS, Siddiqui S, et al. Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali. Int J Tuberc Lung Dis. 2012; 16(7):911–6. doi: 10.5588/ijtld.11.039722508197
48. Winglee K, Manson McGuire A, Maiga M, Abeel T, Shea T, Desjardins CA, et al. Whole Genome Sequencing of Mycobacterium africanum Strains from Mali Provides Insights into the Mechanisms of Geographic Restriction. PLoS Negl Trop Dis. 2016; 10(1):e0004332. doi: 10.1371/journal.pntd.000433226751217.
49. Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun. 2013; 81(8):2909–19. doi: 10.1128/IAI.00632-1323716617
50. Lawson L, Zhang J, Gomgnimbou MK, Abdurrahman ST, Le Moullec S, Mohamed F, et al. A molecular epidemiological and genetic diversity study of tuberculosis in Ibadan, Nnewi and Abuja, Nigeria. PLoS One. 2012; 7(6):e38409. doi: 10.1371/journal.pone.003840922723859
51. Asante-Poku A, Yeboah-Manu D, Otchere ID, Aboagye SY, Stucki D, Hattendorf J, et al. Mycobacterium africanum Is Associated with Patient Ethnicity in Ghana. PLoS Negl Trop Dis. 2015; 9(1):e3370. doi: 10.1371/journal.pntd.000337025569290
52. Gomgnimbou MK, Refregier G, Diagbouga SP, Adama S, Kabore A, Ouiminga A, et al. Spoligotyping of Mycobacterium africanum, Burkina Faso. Emerg Infect Dis. 2012; 18(1):117–9. doi: 10.3201/eid1801.11027522257494.
53. Thumamo BP, Asuquo AE, Abia-Bassey LN, Lawson L, Hill V, Zozio T, et al. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. Infect Genet Evol. 2012; 12(4):671–7. doi: 10.1016/j.meegid.2011.08.01121878397
54. Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis. 2009; 13(3):317–22. 19275790
55. Gehre F, Antonio M, Faihun F, Odoun M, Uwizeye C, de Rijk P, et al. The first phylogeographic population structure and analysis of transmission dynamics of M. africanum West African 1-combining molecular data from Benin, Nigeria and Sierra Leone. PLoS One. 2013; 8(10):e77000. doi: 10.1371/journal.pone.007700024143198
56. Gehre F, Kumar S, Kendall L, Ejo M, Secka O, Ofori-Anyinam B, et al. A Mycobacterial Perspective on Tuberculosis in West Africa: Significant Geographical Variation of M. africanum and Other M. tuberculosis Complex Lineages. PLoS Negl Trop Dis. 2016; 10(3):e0004408. PMCID: 4786107. doi: 10.1371/journal.pntd.000440826964059
57. Zumla A, Maeurer M, Host-Directed Therapies N, Chakaya J, Hoelscher M, Ntoumi F, et al. Towards host-directed therapies for tuberculosis. Nature reviews Drug discovery. 2015; 14(8):511–2. doi: 10.1038/nrd469626184493.
58. Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016; 16(4):e47–63. 27036359. doi: 10.1016/S1473-3099(16)00078-5
59. Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE, Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis. 2012; 54(2):211–9. 22198989. doi: 10.1093/cid/cir788
60. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 371(17):1577–87. 25196020. doi: 10.1056/NEJMoa1407426